


CLAIMS

1. A compound having the formula



5

wherein:

R^1 is H, NO_2 , halo, NR^6R^7 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} haloalkylO, R^6OC_{0-6} alkyl, R^6CO , R^6OCO or $CONR^6R^7$;

m is 0, 1, 2 or 3;

10 R^2 is NO_2 , halo, NR^6R^7 , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} haloalkylO, cyano, R^6OC_{0-6} alkyl, R^6CO , R^6OCO , R^6CONR^7 , R^6R^7NCO , R^8SO_2 , R^8SO_2HN , aryl C_{0-6} alkyl or heteroaryl C_{0-6} alkyl;

R^3 and R^9 are each independently H or C_{1-4} alkyl;

p is 0, 1 or 2;

15 n is 0, 2, 3 or 4;

R^5 is C_{1-10} alkyl, C_{6-10} aryl C_{0-6} alkyl, C_{3-7} cycloalkyl C_{0-6} alkyl or C_{5-6} heteroaryl C_{0-6} alkyl, whereby any aryl, heteroaryl or cycloalkyl may be fused with aryl, heteroaryl, C_{3-7} cycloalkyl or C_{3-7} heterocycloalkyl, and which R^5 may be substituted with one or more A;

20 A is H, OH, NO_2 , cyano, R^6CO , $R^6O(CO)$, halo, C_{1-6} alkyl, NR^6R^7 , C_{1-6} haloalkyl, C_{1-6} haloalkylO, R^6OC_{0-6} alkyl, hydroxy C_{1-6} alkyl, R^8SO_2 , R^8SO_2HN , C_{5-6} arylO or $CONR^6R^7$;

R^6 and R^7 are each independently H or C_{1-6} alkyl; and

R^8 is NR^6R^7 or C_{1-4} alkyl,

25 or salts, solvates or solvated salts thereof.

2. The compound according to claim 1, wherein:

R¹ is H, halo, NR⁶R⁷, C₁₋₆alkyl, C₁₋₆haloalkyl, C₁₋₆haloalkylO, R⁶OC₀₋₆alkyl, R⁶CO, R⁶OCO or CONR⁶R⁷;

m is 0 or 1;

R² is NO₂, halo, NR⁶R⁷, C₁₋₆alkyl, C₁₋₆haloalkyl, cyano, R⁶OCO, R⁶CONR⁷, R⁸SO₂,

5 R⁸SO₂HN or heteroarylC₀₋₆alkyl;

R³ and R⁹ are each independently H or C₁₋₄alkyl;

p is 0;

n is 0;

R⁵ is C₁₋₁₀alkyl, C₆₋₁₀arylC₀₋₆alkyl or C₅₋₆heteroarylC₀₋₆alkyl, whereby any aryl may be

10 fused with C₃₋₇cycloalkyl or C₃₋₇heterocycloalkyl, and which R⁵ may be substituted with one or more A;

A is H, cyano, halo; NO₂, C₁₋₆alkyl, NR⁶R⁷, C₁₋₆haloalkyl, C₁₋₆haloalkylO, R⁶OC₀₋₆alkyl, hydroxyC₁₋₆alkyl, R⁸SO₂ or C₅₋₆arylO;

R⁶ and R⁷ are each independently H or C₁₋₆alkyl; and

15 R⁸ is NR⁶R⁷ or C₁₋₄alkyl,

or salts, solvates or solvated salts thereof.

3. The compound according to claim 1, wherein R² is NO₂, halo, NR⁶R⁷, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₂haloalkylO, cyano, R⁶OC₀₋₄alkyl, R⁶CO, R⁶OCO, R⁶CONR⁷, R⁶R⁷NCO, R⁸SO₂, R⁸SO₂HN, arylC₀₋₆alkyl and heteroaryl and wherein R⁶ and R⁷ are each independently H or C₁₋₄alkyl and R⁸ is NR⁶R⁷ or C₁₋₃alkyl.

4. The compound according to claim 1, wherein R² is nitro.

25 5. The compound according to claim 1, wherein R⁵ is phenyl, which may be substituted with one or more A.

6. The compound according to claim 5, wherein A is selected from the group comprising halo, alkoxy, haloalkoxy, haloalkyl, alkyl, alkanol, cyano, phenoxy, alkylsulfonyl and
30 (di)alkylamino.

7. The compound according to claim 1, wherein A is selected from the group consisting fluoro, iodo, chloro, bromo, methoxy, ethoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, tetrafluoroethoxy, methyl, ethyl, propyl, butyl, hydroxyethyl, cyano, phenoxyethylsulfonyl and dimethylamino.

5

8. The compounds selected from the group consisting

N-(3-Fluoro-4-methoxy-phenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)-acetamide,

N-[2-Fluoro-4-(trifluoromethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(3-Chloro-4-iodophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

10 *N*-(3-Chloro-4-methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-[3-(Difluoromethoxy)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(3,5-Difluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)phenyl]acetamide,

15 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]acetamide,

N-(4-*tert*-Butylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-[3-(1-Hydroxyethyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)phenyl]acetamide,

N-(3-Chlorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

20 *N*-Hexyl-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(3,4-Difluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(4-Cyanophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(2-Bromobenzyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

25 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)benzyl]acetamide,

N-(4-Methylpyridin-2-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(3-Cyanophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(3,5-Dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(4-Methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

30 *N*-(3-Ethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

N-(3,4-Dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,

2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(3,4,5-trimethoxyphenyl)acetamide,

2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethoxy)phenyl]acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(3-phenoxyphenyl)acetamide,
N-(4-Butylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(2-Fluoro-4-iodophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
5 2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[2-(trifluoromethoxy)phenyl]acetamide,
N-(4-Methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-(2-phenoxyphenyl)acetamide,
10 *N*-(4-Bromo-2-fluorophenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-[3-(Methylsulfonyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
15 *N*-[4-(Methylsulfonyl)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethyl)benzyl]acetamide,
N-(4-*tert*-Butylbenzyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
20 *N*-(2,3-dihydro-1*H*-inden-5-yl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[4-(trifluoromethoxy)benzyl]acetamide,
15 *N*-(4-Isopropylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,4-Dimethylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-1,3-Benzodioxol-5-yl-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
25 *N*-[3-Bromo-4-(trifluoromethoxy)phenyl]-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
N-(3-Fluoro-2-methoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
20 *N*-(3,5-dimethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)propanamide,
N-(3-Ethoxyphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)propanamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]propanamide,
25 *N*-(3,5-Dimethylphenyl)-2-(7-nitro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-(3-methoxyphenyl)acetamide,
2-(7-Bromo-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
30 2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(4-methylphenyl)acetamide,
2-(7-Chloro-1*H*-benzimidazol-1-yl)-*N*-(2,3-dihydro-1*H*-inden-5-yl)acetamide,
2-(7-Methyl-1*H*-benzimidazol-1-yl)-*N*-(4-methylphenyl)acetamide,

N-(3,5-Dimethoxyphenyl)-2-(7-methyl-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Methyl-1*H*-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
N-(2,3-Dihydro-1*H*-inden-5-yl)-2-(7-methyl-1*H*-benzimidazol-1-yl)acetamide,
Methyl 1-{2-[(3,4-dimethylphenyl)amino]-2-oxoethyl}-1*H*-benzimidazole-7-carboxylate,
5 Methyl 1-[2-(2,3-dihydro-1*H*-inden-5-ylamino)-2-oxoethyl]-1*H*-benzimidazole-7-carboxylate,
Methyl 1-{2-[(4-*tert*-butylbenzyl)amino]-2-oxoethyl}-1*H*-benzimidazole-7-carboxylate,
Methyl 1-(2-{[3-methoxy-5-(trifluoromethyl)phenyl]amino}-2-oxoethyl)-1*H*-benzimidazole-7-carboxylate,
10 Methyl 1-{2-[(3,5-dimethoxyphenyl)amino]-2-oxoethyl}-1*H*-benzimidazole-7-carboxylate,
N-(3,5-Dimethoxyphenyl)-2-{7-[(dimethylamino)sulfonyl]-1*H*-benzimidazol-1-yl}acetamide,
2-{7-[(Dimethylamino)sulfonyl]-1*H*-benzimidazol-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide,
15 N-(3,5-Dimethoxyphenyl)-2-[7-(propylsulfonyl)-1*H*-benzimidazol-1-yl]acetamide,
2-[7-(Propylsulfonyl)-1*H*-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
N-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-[7-(methylsulfonyl)-1*H*-benzimidazol-1-yl]acetamide,
20 N-(3,5-Dimethoxyphenyl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
N-(3,4-Dimethylphenyl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
N-(4-*tert*-Butylbenzyl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
N-(2,3-Dihydro-1*H*-inden-5-yl)-2-[7-(trifluoromethyl)-1*H*-benzimidazol-1-yl]acetamide,
2-(7-Cyano-1*H*-benzimidazol-1-yl)-N-(3,5-dimethoxyphenyl)acetamide,
25 2-(7-Cyano-1*H*-benzimidazol-1-yl)-N-(3-methoxyphenyl)acetamide,
2-(7-Cyano-1*H*-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
2-(7-Cyano-1*H*-benzimidazol-1-yl)-N-(2,3-dihydro-1*H*-inden-5-yl)acetamide,
N-(2,3-Dihydro-1*H*-inden-5-yl)-2-(7-fluoro-1*H*-benzimidazol-1-yl)acetamide,
N-(3,5-Dimethoxyphenyl)-2-(7-fluoro-1*H*-benzimidazol-1-yl)acetamide,
30 N-(4-*tert*-Butylbenzyl)-2-(7-fluoro-1*H*-benzimidazol-1-yl)acetamide,
2-(7-Amino-1*H*-benzoimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
2-[7-(Acetylamino)-1*H*-benzoimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,

2-{7-[(Methylsulfonyl)amino]-1H-benzimidazol-1-yl}-N-[3-(trifluoromethyl)phenyl]acetamide,
2-[7-(Dimethylamino)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
2-[7-(Isopropylamino)-1H-benzimidazol-1-yl]-N-[3-(trifluoromethyl)phenyl]acetamide,
5 N-(3,5-Dimethoxyphenyl)-2-[7-(1H-tetrazol-5-yl)-1H-benzimidazol-1-yl]acetamide,
and
2-(6,7-Difluoro-1H-benzimidazol-1-yl)-N-[3-(trifluoromethyl)phenyl]acetamide,
or salts, solvates or solvated salts thereof.

10 9. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 to 8, in association with one or more pharmaceutically acceptable diluents, excipients and/or inert carriers.

15 10. The pharmaceutical composition according to claim 9, for use in the treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, and respiratory diseases.

11. The compound according to any one of claims 1 to 8, for use in therapy.

20 12. Use of the compounds of formula I according to any one of claims 1 to 8, in the manufacture of a medicament for treatment of VR1 mediated disorders.

13. The use according to claim 12 for treatment of acute and chronic pain disorders.

25 14. The use according to claim 12 for treatment of acute and chronic neuropathic pain.

15. The use according to claim 12 for treatment of acute and chronic inflammatory pain.

30 16. The use according to claim 12 for treatment of arthritis, fibromyalgia, low back pain, post-operative pain, visceral pains like chronic pelvic pain, cystitis, irritable bowel syndrome (IBS), pancreatitis, ischeamic, sciatica, diabetic neuropathy, multiple sclerosis, interstitial cystitis and pain related to interstitial cystitis, HIV neuropathy, asthma, cough

and inflammatory bowel disease (IBD), gastro-esophageal reflux disease (GERD), psoriasis, cancer, emesis, urinary incontinence and hyperactive bladder.

17. The use according to claim 12 for treatment of respiratory diseases.

5

18. A method of treatment of VR1 mediated disorders and for treatment of acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, and respiratory diseases, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the

10 compounds of formula I, according to any one of claims 1 to 8.

19. Compounds selected from the group consisting

(7-Nitro-1*H*-benzimidazol-1-yl)acetonitrile,

(7-Nitro-1*H*-benzimidazol-1-yl)acetic acid,

2-(7-Nitro-1*H*-benzimidazol-1-yl)propanenitrile,

2-(7-nitro-1*H*-benzimidazol-1-yl)propanoic acid,

2-[(2-Bromo-6-nitrophenyl)amino]ethanol,

2-[(2-Amino-6-bromophenyl)amino]ethanol,

2-(7-Bromo-1*H*-benzimidazol-1-yl)ethanol,

20 (7-Bromo-1*H*-benzimidazol-1-yl)acetic acid,

8-Chloro-3-oxo-3,4-dihydroquinoxaline-1(2*H*)-carbaldehyde,

2-[(2-Amino-6-chlorophenyl)amino]ethanol,

2-(7-Chloro-1*H*-benzimidazol-1-yl)ethanol,

(7-Chloro-1*H*-benzimidazol-1-yl)acetic acid,

25 (2-Methyl-6-nitrophenyl)formamide,

Ethyl *N*-formyl-*N*-(2-methyl-6-nitrophenyl)glycinate,

Ethyl *N*-(2-amino-6-methylphenyl)-*N*-formylglycinate,

(7-Methyl-1*H*-benzimidazol-1-yl)acetic acid,

2-[(2-Hydroxyethyl)amino]-3-nitrobenzoic acid,

30 Methyl 2-[(2-hydroxyethyl)amino]-3-nitrobenzoate,

Methyl 1-(2-hydroxyethyl)-1*H*-benzimidazole-7-carboxylate,

3-Carboxymethyl-3*H*-benzimidazole-4-carboxylic acid methyl ester,

2-Chloro-*N,N*-dimethyl-3-nitrobenzenesulfonamide,

2-[(2-Hydroxyethyl)amino]-*N,N*-dimethyl-3-nitrobenzenesulfonamide,

3-Amino-2-[(2-hydroxyethyl)amino]-*N,N*-dimethylbenzenesulfonamide,

1-(2-Hydroxyethyl)-*N,N*-dimethyl-1*H*-benzimidazole-7-sulfonamide,

5 (7-Dimethylsulfamoyl-benzimidazol-1-yl)-acetic acid,

2-Chloro-1-nitro-3-(propylsulfonyl)benzene,

2-{[2-Nitro-6-(propylsulfonyl)phenyl]amino}ethanol,

2-{[2-Amino-6-(propylsulfonyl)phenyl]amino}ethanol,

[7-(Propylsulfonyl)-1*H*-benzimidazol-1-yl]acetic acid,

10 [7-(Methylsulfonyl)-1*H*-benzimidazol-1-yl]acetic acid,

2-(7-(Methylsulfonyl)-1*H*-benzimidazol-1-yl)-ethanol,

2-{[2-Nitro-6-(trifluoromethyl)phenyl]amino}ethanol,

2-{[2-amino-6-(trifluoromethyl)phenyl]amino}ethanol,

2-[7-(Trifluoromethyl)-1*H*-benzimidazol-1-yl]ethanol,

15 [7-(Trifluoromethyl)-1*H*-benzimidazol-1-yl]acetic acid,

2-[(2-hydroxyethyl)amino]-3-nitrobenzonitrile,

1-(2-hydroxyethyl)-1*H*-benzimidazole-7-carbonitrile,

(7-Cyano-1*H*-benzimidazol-1-yl)acetic acid,

2-[(2-Fluoro-6-nitrophenyl)amino]ethanol,

20 2-(7-Fluoro-1*H*-benzoimidazol-1-yl)ethanol, and

(7-Fluoro-1*H*-benzimidazol-1-yl)acetic acid,

20. Use of compounds according to claim 19 as intermediates in the preparation of the compound of formula I.

25

21. The compounds selected from the group consisting

2-(1*H*-Benzimidazol-1-yl)-*N*-(3-(trifluoromethyl)phenyl)propanamide,

2-(1*H*-Benzimidazol-1-yl)-*N*-(3-chloro-4-fluorophenyl)acetamide,

2-(1*H*-Benzimidazol-1-yl)-*N*-(3-fluoro-4-methylphenyl)acetamide,

30 2-(1*H*-Benzimidazol-1-yl)-*N*-(3,4-difluorophenyl)acetamide,

2-(4-Methyl-1*H*-benzimidazol-1-yl)-*N*-(3-(trifluoromethyl)phenyl)acetamide,

2-(4,5-Difluoro-1*H*-benzimidazol-1-yl)-*N*-(3-(trifluoromethyl)phenyl)acetamide,

2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(dimethylamino)phenyl]acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)benzyl]acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(4-chlorobenzyl)acetamide,
5 2-(1*H*-Benzimidazol-1-yl)-*N*-(3,5-dimethoxyphenyl)acetamide,
3-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)propanamide,
4-(1*H*-Benzimidazol-1-yl)-*N*-(4-*tert*-butylphenyl)butanamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-(2-methyl-1,3-benzothiazol-5-yl)acetamide,
2-(1*H*-Benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
10 2-(4-Amino-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(5-Fluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(6-Fluoro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(4-Nitro-1*H*-benzimidazol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, and
2-(1*H*-Benzimidazol-1-yl)-*N*-heptylacetamide,
15 or salts, solvates or solvated salts thereof.

22. The compounds selected from the group consisting

2-(1*H*-Indol-1-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
2-(5-Fluoro-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide, and
20 2-(1-Methyl-1*H*-indol-3-yl)-*N*-[3-(trifluoromethyl)phenyl]acetamide,
or salts, solvates or solvated salts thereof.